PLCγ2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2

Excessive bone loss in arthritic diseases is mostly due to abnormal activation of the immune system leading to stimulation of osteoclasts. While phospholipase Cγ (PLCγ) isoforms are known modulators of T and B lymphocyte–mediated immune responses, we found that blockade of PLCγ enzymatic activity also blocks early osteoclast development and function. Importantly, targeted deletion of Plcg2 in mice led to an osteopetrotic phenotype. PLCγ2, independent of PLCγ1, was required for receptor activator of NF-κB ligand–induced (RANKL-induced) osteoclastogenesis by differentially regulating nuclear factor of activated T cells c1 (NFATc1), activator protein–1 (AP1), and NF-κB. Specifically, we show that NFATc1 upregulation is dependent on RANKL-mediated phosphorylation of PLCγ2 downstream of Dap12/Fc receptor γ (Dap12/FcRγ) receptors and is blocked by the PLCγ inhibitor U73122. In contrast, activation of JNK and NF-κB was not affected by U73122 or Dap12/FcRγ deletion. Interestingly, we found that in osteoclasts, PLCγ2 formed a complex with the regulatory adapter molecule GAB2, was required for GAB2 phosphorylation, and modulated GAB2 recruitment to RANK. Thus, PLCγ2 mediates RANKL-induced osteoclastogenesis and is a potential candidate for antiresorptive therapy.

Bone erosion is a major hallmark of rheumatoid arthritis and is solely executed by the bone-resorbing cells, the osteoclasts (OCs) (1). These cells arise from macrophage precursors and differentiate into the mature polykaryon after stimulation with receptor activator of NF-κB ligand (RANKL) and M-CSF (2). OCs are recruited to sites of inflammation or differentiate at these sites owing to elevated levels of local RANKL secreted by cells in the inflamed tissue. Levels of TNF-α, IL-1, and M-CSF are also elevated during inflammatory responses and they collaborate with RANKL to further increase the rate of OC formation and bone resorption (3–6).

Binding of RANKL to receptor activator of NF-κB (RANK) leads to receptor trimerization, followed by the recruitment of TRAF6, which acts as a key adapter to assemble signaling proteins that direct OC-specific gene expression (2). Both NF-κB and activator protein–1 (AP1) are rapidly induced in response to RANKL, following the activation of IκB kinase 1/2 (IKK1/2) and JNK, respectively (2, 7–9). Interfering with IKK1/2 or JNK1 signaling pathways blocks in vitro and in vivo osteoclastogenesis (10–12). Targeted mutagenesis of the p50/p52 components of NF-κB (13, 14) as well as the c-Fos component of AP1 (15) results in osteopetrosis due to a block in osteoclastogenesis. Further, a recent finding indicates that activation of JNK and NF-κB pathways requires the phosphorylation and the recruitment of the Grb2-binding adapter protein, GAB2, to RANK (16). Consistent with these observations, GAB2^–/– mice exhibit an osteopetrotic phenotype due to aberrant OC differentiation (16).

In addition to the known roles of AP1 and NF-κB pathways in osteoclastogenesis, recent studies have highlighted the role of the nuclear factor of activated T cells c1 (NFATc1), a calcineurin- and calcium-regulated transcription factor, as a master transcription factor in this process (17, 18). The importance of NFATc1 in OC development has been buttressed by the fact that NFATc1^–/– embryonic stem cells cannot differentiate into OCs. Furthermore, overexpression of the WT protein stimulates OC development from embryonic stem cells in a RANKL-independent manner (18). Interestingly, the ability of NFATc1 to mediate osteoclastogenesis is strictly connected to the c-Jun pathway (19). Transgenic mice expressing a dominant negative form of c-Jun have osteopetrosis due to defective osteoclastogenesis that cannot be rescued by NFATc1 overexpression in OCs (19).

Immune receptor tyrosine activation motifs (ITAMs) are important signaling components for a number of receptors in the immune system, and they have been recently identified as costimulatory signals in RANKL-induced osteoclastogenesis (20). The 2 ITAM-containing adapters, Dap12 and the γ chain of Fc receptor (FcRγ), have a profound impact on OCs by modulating RANKL-mediated calcium influx and NFATc1 expression. In humans, mutation in the Dap12 gene is responsible for Nasu-Hakola disease, characterized by multiple bone cysts associated with a unique form of neurodegeneration (21). Deletion of Dap12 and FcRγ (Dap12^–/–FcRγ^–/–), in mice, leads to severe osteopetrosis due to defective OC development (20–22). In vitro triggering of either receptor by crosslinking with an antibody accelerates RANKL-induced OC differentiation (23). However, in the absence of RANKL, these receptor-mediated signals alone are not sufficient to induce OC differentiation.

The phospholipase C (PLC) family regulates PKC activation, intracellular calcium levels, and NFAT expression in hematopoietic systems in response to the stimulation of immune receptors (24–27). PLC cleaves the membrane phospholipid phosphatidyl inositol-4,5-biphosphate (PIP2) into the second messenger molecules inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 directly increases intracellular calcium levels by inducing the release of endoplasmic reticulum calcium stores, while DAG activates PKC at the plasma membrane.

The PLCγ family consists of 2 members, PLCγ1 and PLCγ2 (24–26). Both isoforms require phosphorylation on specific tyrosine residues for their catalytic activity. In addition, they contain 2 SH2 and 1 SH3 domains through which they can interact with other signaling proteins, suggesting adapter function. PLCγ1 is widely distributed, while PLCγ2 is primarily limited to cells of hematopoietic lineage (24). Mice deficient in PLCγ1 develop normally to embryonic day 8.5 but die soon after due to undefined defects in growth and development (28). The disruption of PLCγ2 in mice does not result in embryonic lethality, but animals show internal bleeding, decreased B cell number and function, defective platelet aggregation to collagen, and a block in Fc receptor–mediated responses in mast cells and NK cells (29–31).

Although NF-κB, AP1, and NFATc1 are all critical for RANKL-induced osteoclastogenesis (9, 18, 32), due to their ubiquitous expression, selective therapies targeting these signaling pathways in OCs are not yet in clinical use. In this study, we show that targeted deletion of Plcg2 in mice results in an in vivo osteopetrotic phenotype, independent of PLCγ1. In vitro, Plcg2-null cells fail to form multinucleated OCs and exhibit decreased RANKL-mediated NFATc1 expression; impaired JNK, c-Jun, and IκBα phosphorylation; and thus defective AP1 and NF-κB activation. Our data reveal a role for PLCγ2 in bone homeostasis apart from its contribution to B cell development. The combined effect of PLCγ2 on lymphocyte and OC differentiation could represent a novel target for the treatment of inflammatory osteolytic diseases.

Inhibition of PLCγ enzymatic activity blocks OC differentiation and disrupts actin ring formation. PLCγ isoforms are known activators of the NFAT family of transcription factors in lymphoid cells, downstream of immune receptor signaling via ITAMs (33). Since NFAT and ITAMs are both critical regulators of OC differentiation and cells lacking the ITAM-containing adapters Dap12/FcRγ display severe osteopetrosis (20), we asked whether PLCγ family members were also required for efficient OC differentiation and function. We therefore tested the capacity of the PLCγ inhibitor U73122 to block OC formation and bone resorption. Addition of U73122 to the culture media blocked OC development, as demonstrated by the absence of tartrate-resistant acid phosphatase–positive (TRAP-positive) cells, compared with the numerous multinucleated OCs obtained in wells cultured only with RANKL and M-CSF (Figure 1A). Replacing the media with fresh osteoclastogenic media lacking the inhibitor restored the ability of the cells to differentiate, indicating that the compound was not toxic to the cells (Figure 1A). Culture of OCs on dentin in the presence of U73122 blocked bone resorption (Figure 1B). Furthermore, addition of U73122 to mature resorbing cells rapidly disrupted the organization of the actin rings, indicating that this compound can block bone resorption independent of its capacity to affect differentiation (Figure 1C).

Figure 1

PLCγ inhibition blocks osteoclastogenesis and actin ring formation. (A) WT OCs were generated with RANKL (100 ng/ml) and M-CSF (10 ng/ml) in the presence of the PLC inhibitor U73122 (5 μM) for 4 days on plastic. In some wells, the media with the inhibitor was replaced with fresh osteoclastogenic media, and cells were allowed to differentiate for 4 more days (Withdrawal U73122). (B) WT OCs were grown on dentin with or without U73122 for 10 days. Cells were then removed and pits stained with hematoxylin red (Magnification, ×200). CTR, control. (C) WT OCs were generated on dentin in the absence of the inhibitor, then treated with vehicle or U73122 for 1 hour. Cells were fixed and actin stained using FITC-phalloidin (Magnification, ×200).

PLCγ2 regulates bone mass in vivo. To determine whether PLCγ1, PLCγ2, or both are required for OC formation, we turned to the analysis of mice lacking these proteins. Plcg1^–/– mice die in utero by day 9, rendering the analysis of their bone phenotype difficult. Plcg2^–/– mice, however, are viable. Thus, femurs from 4-month-old sex-matched WT and Plcg2^–/– mice were subjected to histological examination (Figure 2, A–E) and μCT analysis (Figure 2, F–I). Plcg2^–/– mice had a more than 3-fold increase in the percentage of trabecular bone volume versus total bone volume compared with their WT counterparts, as determined by histological examination (Figure 2B) and as shown in μCT reconstructed 3D images (Figure 2F). Histomorphometric analysis also indicated that the number of osteoblasts (OBs) per bone perimeter was similar in WT and Plcg2^–/– mice (Figure 2C), while the number of OCs per bone perimeter and the OC surface were significantly decreased in the null animals (Figure 2, D and E). The number of the trabeculae (Figure 2G) and their thickness (Figure 2H) were significantly higher in the Plcg2^–/– compared with WT mice, while the space between the trabeculae was smaller (Figure 2I). Thus, PLCγ2 regulates bone mass in vivo.

Figure 2

Osteopetrosis in mice lacking PLCγ2. (A) TRAP staining of decalcified histological sections of WT and Plcg2^–/– proximal femurs. Magnification, ×40. (B–E) Quantitative analysis of bone parameters from histological sections of WT and Plcg2^–/– bone femurs (n = 8) showing: percentage of bone volume versus total bone volume (BV/TV) (B); number of OBs (nOB) per bone perimeter (C); number of OCs (nOC) per bone perimeter (D); fraction of trabecular surface covered by OCs (E). (F) 3D reconstitution of μCT scans of WT and Plcg2^–/– femurs. (G–I) 3D trabecular quantitative parameters of bone structure (n = 6). Graphs show mean ± SEM, with significant differences compared with WT indicated.

PLCγ2 is required for OC differentiation. To determine whether PLCγ2 modulates the capacity of OBs to form bone or to promote OC differentiation, primary OBs were isolated from newborn mice, and their capacity to mineralize extracellular matrix or induce osteoclastogenesis in a coculture system was examined. Plcg2^–/– OBs were indistinguishable from their WT counterparts in their ability to form bone nodules in response to β-glycerolphosphate (WT, 14 ± 2.08 nodules/well versus Plcg2^–/–, 14.6 ± 1.65 nodules/well) (Figure 3A). This finding was also supported by the in vivo analysis of bone mineral apposition determined by calcein double-labeling (Figure 3B), which revealed no significant difference in bone formation rates (BFRs) and mineral apposition rates (MARs) between WT (BFR, 0.8938 ± 0.1042 μm³/μm²/d; MAR, 0.5927 ± 0.0219 μm/d) and Plcg2^–/– animals (BFR, 0.8450 ± 0.1629 μm³/μm²/d; MAR, 0.4015 ± 0.0876 μm/d). To determine whether Plcg2^–/– OBs are capable of supporting OC differentiation, BM macrophages (BMMs) from WT mice were cocultured with either WT or Plcg2^–/– OBs in the presence of 1,25 vitamin D₃ (1,25 Vit D₃). Cultures were stained for TRAP to identify OCs. WT BMMs became TRAP-positive, multinucleated cells when cultured with WT OBs (OCs, 9 ± 1.07/well) or null OBs (OCs, 7 ± 0.44/well), indicating that the expression of PLCγ2 in OBs is not required to support osteoclastogenesis. However, in a parallel experiment, BMMs from Plcg2^–/– mice failed to form mature OCs in the coculture system, independent of the source of the OBs (Figure 3C). These results suggest that the increased in vivo bone mass observed in Plcg2^–/– mice was not due to aberrant OB activity but was dependent on an intrinsic defect in the OC lineage. We therefore cultured primary BMMs with M-CSF and RANKL for 5 days, in the absence of OBs or stromal cells. The osteoclastogenic response of Plcg2^–/– BMMs to RANKL and their capacity to resorb bone were arrested (Figure 3D; WT OCs, 33.2 ± 1.74/well versus Plcg2^–/– OCs, not detected). Increasing the concentration of M-CSF from 10 to 100 ng/ml, a condition that partially rescued the osteoclastogenesis in cells lacking the ITAM-bearing adapter Dap12 (34), did not enhance Plcg2^–/– OC differentiation (data not shown).

Figure 3

PLCγ2 is required for osteoclastogenesis. (A) Bone nodule formation in WT and Plcg2^–/– OBs cultured with ascorbic acid and β-glycerolphosphate. (B) Double labeling of calvarial bones showing the degree of bone formation (BFR) of WT and Plcg2^–/– mice injected on day 0 and day 7 with calcein (WT BFR, 0.8938 ± 0.1042 μm³/μm²/d; WT mineral apposition rate [MAR], 0.5927 ± 0.0219 μm/d; Plcg2^–/– BFR, 0.8450 ± 0.1629 μm³/μm²/d; Plcg2^–/– MAR, 0.4015 ± 0.0876 μm/d). (C) WT and Plcg2^–/– BMMs cultured with WT and Plcg2^–/– OBs in the presence of 10^–8 M 1,25 Vit D₃. After 14 days, cells were fixed and TRAP stained to detect the presence of multinucleated OCs. (D) TRAP-stained OCs generated with RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 5 days (top panel) and bone resorptive pits generated from OCs plated on dentin for 7 days. Pits were stained with hematoxylin red. (E) WT and Plcg2^–/– BMMs retrovirally transduced with vector alone (pMX) or with Flag-tagged PLCγ2 were allowed to differentiate in osteoclastogenic media for 5 days, then stained for TRAP. Magnification, ×200 (A, C–E); ×100 (B).

To determine which stage of OC differentiation is PLCγ2 dependent, the levels of early osteoclastogenic markers TRAP, cathepsin K, NFATc1, and calcitonin receptor, a late OC marker, were determined by real-time PCR analysis in BMMs cultured with RANKL (100 ng/ml) and M-CSF (10 ng/ml) up to 4 days. The expression of TRAP, cathepsin K, and NFATc1 increased within 24–48 hours after RANKL stimulation in WT but not in Plcg2^–/– cells (not shown). On day 4, the levels of these genes were maximal in WT cells but dramatically lower in the null cells (Figure 4, A–D). Similarly, calcitonin receptor was detected after 4 days of treatment with RANKL only in WT OCs, suggesting that Plcg2^–/– cells have an early block of OC development. Confirming mRNA expression, protein levels of NFATc1 were significantly higher in total cell lysates of day 4 WT OCs than in null cells, both under basal conditions and following 60 minutes of RANKL stimulation (Figure 4E). Together, these data indicate that PLCγ2 is required at early stages of OC development.

Figure 4

PLCγ2 regulates NFATc1 levels and the expression of early osteoclastogenic genes. (A–D) Real-time PCR analysis of osteoclastogenic markers in WT and Plcg2^–/– cells in culture with M-CSF alone (d0) or with RANKL (100 ng/ml) plus M-CSF (10 ng/ml) for 4 days (d4). Data are normalized relative to β-actin. ND, not detected. Significant differences compared with WT are shown. (E) Expression levels of NFATc1 protein in total cell lysates from day 4 WT and Plcg2^–/– OCs, starved for 6 hours and stimulated with RANKL for 0, 5, 20, and 60 minutes. PLCγ1 and PLCγ2 levels are shown. β-Actin served as loading control.

PLCγ2 is required for efficient RANKL-induced activation of AP1 and NF-κB in developing OCs. To further understand whether PLCγ2 is a downstream mediator of RANKL, M-CSF, or both during OC differentiation, we analyzed MAPK activation by BMMs in culture with M-CSF for 3 days. Activation of ERK and JNK in response to M-CSF occurred normally in BMMs lacking PLCy2 (Figure 5A). Similarly, ERK was normally phosphorylated in the null cells in response to RANKL (Figure 5B). In contrast, RANKL-mediated JNK phosphorylation was retarded and reduced in the absence of PLCγ2 (Figure 5B), and activation of c-Jun (by phosphorylation) was also decreased in both the cytoplasm and the nucleus (Figure 5, B and C). This result is particularly compelling, since JNK/c-Jun activates the AP1 complex, and inhibition of JNK activity blocks RANKL-induced OC development (19). Thus, to determine whether the decreased phosphorylation of JNK observed in Plcg2^–/– BMMs stimulated with RANKL could result in deficient AP1 activation, nuclear extracts from WT and Plcg2^–/– cells were subjected to EMSA analysis following RANKL stimulation. The activation of AP1 was abolished in RANKL-stimulated Plcg2^–/– BMMs (Figure 5D, top panel).

Figure 5

PLCγ2 modulates RANKL-mediated signaling. (A) Activation of ERK and JNK in WT and Plcg2^–/– BMMs in response to M-CSF (100 ng/ml). PLCγ1 and PLCγ2 levels are shown. (B) Western blot analysis of phospho-ERK, phospho-JNK, phospho–c-Jun, and phospho-IκBα in total cell lysates from WT and Plcg2^–/– BMMs stimulated with RANKL (100 ng/ml) for the indicated times. β-Actin blots served as loading control for A and B. (C) Nuclear levels of phospho–c-Jun and p65 in nuclear extracts from WT and Plcg2^–/– BMMs stimulated with RANKL. (D) The same samples used in C were subjected to AP1 and NF-κB nonradioactive EMSA analysis. To control for binding specificity, a concentration of unlabeled oligonucleotides (U.O.) 200-fold greater than that recommended by the manufacturer was added to nuclear extracts from WT cells stimulated with RANKL for 60 minutes. SP1 served as loading control for C and D.

Since NF-κB is the other major signaling pathway required for efficient osteoclastogenesis, and PLCγ isoforms have been shown to modulate T cell and B cell receptor–mediated NF-κB activation, we hypothesized that this pathway could also be regulated by PLCγ2 in OCs. Nuclear extracts from WT and Plcg2^–/– BMMs stimulated with RANKL were subjected to EMSA analysis, and data show that in the null cells, activation of NF-κB was virtually absent (Figure 5D, bottom panel). In agreement with this result, IκBα phosphorylation and nuclear translocation of p65 were also decreased in Plcg2^–/– BMMs (Figure 5, B and C). Collectively, these data suggest that PLCγ2 plays a central role in RANKL-mediated osteoclastogenesis by controlling activation of AP1 and NF-κB and upregulation of NFATc1.

PLCγ2 is phosphorylated by RANKL via Dap12-mediated costimulatory signals in a Src family kinase–dependent manner. Having shown that PLCγ2 is required for the activation of osteoclastogenic signaling pathways downstream of RANKL, we turned to the mechanism by which PLCγ2 itself is activated in OCs. In immune cells, PLCγ isoforms are tyrosine phosphorylated in a Src family kinase–dependent (SFK-dependent) manner (24). Incubation of WT cells with the SFK inhibitor PP2 (5 μM) completely blocked RANKL-mediated PLCγ2 phosphorylation and NFATc1 upregulation (Figure 6A), demonstrating a concordant dependence on SFK in OC lineage cells.

Figure 6

PLCγ2 is activated by RANKL via Dap12/FcRγ in an SFK-dependent manner. (A) WT OC precursors (preOCs; BMMs grown in RANKL-containing media for 2 days) cultured with the SFK inhibitor PP2 (5 μM) or vehicle (DMSO) were stimulated with RANKL and subjected to Western blot analysis to detect phosphorylated levels of PLCγ2, Src, and NFATc1. β-Actin served as control. (B) PLCγ1 and PLCγ2 phosphorylation in response to RANKL were measured by Western blot analysis in WT and Plcg2^–/– preOCs. PLCγ1 and PLCγ2 levels are shown. (C) PLCγ1 and PLCγ2 phosphorylation in response to 5 minutes of treatment with either M-CSF or RANKL in WT and Plcg2^–/– preOCs. β-Actin served as control. (D) Expression levels of endogenous Dap12 and Flag-tagged Dap12 retrovirally transduced in Dap12^–/–FcRγ^–/– BMMs are shown. ΔKO, Dap12^–/–FcRγ^–/–. (E) PLCγ2 phosphorylation was measured by Western blot analysis in WT, Dap12^–/–FcRγ^–/–, or Dap12^–/–FcRγ^–/– preOCs reconstituted with WT Dap12 stimulated with RANKL for the indicated times. Phospho-JNK is also shown. β-Actin served as loading control. (F) Nuclear localization of NFATc1 in WT and Dap12^–/–FcRγ^–/– OCs retrovirally transduced with pMX or Flag-tagged Dap12 is shown in red (left panels). Actin staining is shown in green, and nuclei, stained with DAPI, are shown in blue (right panels) (objective, ×20). Enlarged images (2.5-fold) show nuclear localization of NFATc1 (red) and nuclei stained with DAPI (blue) of representative cells located in the center of the photographed field.

To determine whether lack of PLCγ2 was abrogating the activation of PLCγ1 in response to RANKL and M-CSF, WT and Plcg2^–/– OC precursors (BMMs grown in RANKL-containing media for 2 days) were stimulated with RANKL or M-CSF. Interestingly, RANKL-mediated PLCγ1 phosphorylation was barely measurable in both WT cells and cells lacking PLCγ2 (Figure 6B) despite detectable levels of PLCγ1 protein in both cell types. In contrast, a strong PLCγ1 phosphorylation signal was observed after M-CSF stimulation in WT and Plcg2^–/– cells (Figure 6C).

Since costimulatory signals are required for RANKL-mediated calcium oscillation and NFATc1 expression, we determined whether PLCγ2 phosphorylation was dependent on the RANKL costimulatory receptors Dap12 and FcRγ. We found that PLCγ2 phosphorylation and NFATc1 nuclear localization were decreased in Dap12^–/–FcRγ^–/– cells treated with RANKL (Figure 6, E and F). Reexpression of Dap12, but not empty vector, in the double null OCs (Figure 6D) completely restored PLCγ2 phosphorylation (Figure 6E) and expression of NFATc1 in the nucleus (Figure 6F). Thus, PLCγ2 is phosphorylated downstream of Dap12 in an SFK-dependent manner, following RANKL stimulation.

PLCγ2 catalytic activity is required for NFATc1 upregulation but not for JNK and IκBα phosphorylation. Our data indicate that PLCγ2 regulates NFATc1 and activates JNK and IκBα. In contrast, Dap12/FcRγ modulates NFATc1 (Figure 6F) but not JNK (Figure 6E) or IκBα (20). Thus, we hypothesized that PLCγ2 regulates JNK and IκBα independent of Dap12/FcRγ. To determine whether PLCγ2 catalytic activity is required for JNK and IκBα phosphorylation, WT OC precursors, cultured in the presence of the PLC inhibitor U73122 (5 μM), were stimulated with RANKL for 0 to 60 minutes (Figure 7A). While dampening NFATc1 upregulation, the inhibitor had no effect on p-JNK and p-IκBα, suggesting that the catalytic activity of PLCγ2 is not required for phosphorylation of JNK and IκBα.

Figure 7

PLCγ2 forms a complex with GAB2 and modulates its activation. (A) WT preOCs cultured with or without the PLC inhibitor U73122 (5 μM) for 3 days were stimulated with RANKL and subjected to Western blot analysis for phospho-JNK, phospho-IκBα, and NFATc1. β-Actin served as control. (B) WT and Plcg2^–/– BMMs retrovirally transduced with empty vector (pMX), WT PLCγ2, or catalytically inactive PLCγ2 (PLCγ2 H/F) were cultured with RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 7 days, and multinucleated OCs were detected by TRAP staining. Objective, ×10. (C) The same cells as shown in B were subjected to RANKL stimulation and Western blot analysis to detect NFATc1 expression. (D) Plcg2^–/– BMMs retrovirally transduced with pMX, WT PLCγ2, or PLCγ2 H/F were treated with RANKL, and phosphorylation of IκBα and JNK was determined by Western blot analysis. PLCγ2 expression levels are shown. β-Actin served as loading control in C and D. (E) PLCγ2 and GAB2 were reciprocally immunoprecipitated in WT and Plcg2^–/– BMMs treated with RANKL and subjected to Western blot analysis using anti-PLCγ2 and anti-GAB2 Abs, respectively. TCL, total cell lysate. (F) GAB2 was immunoprecipitated in WT and Plcg2^–/– BMMs and subjected to Western blot analysis using anti-phosphotyrosine Ab (clone 4G10), anti-RANK, and anti-PLCγ2.

Mutations of 2 histidine residues, conserved among all PLC family members, have been shown to inhibit the enzymatic activity of PLCγ1 by 90%–95% in vitro (35). Thus, we generated a PLCγ2 catalytic inactive construct carrying the double histidine 327/372 to phenylalanine mutation (PLCγ2 H/F). This mutant was proven to be lipase inactive compared with WT full-length PLCγ2 in 293 cells (data not shown). Plcg2^–/– cells transduced with PLCγ2 H/F were incapable of generating mature, TRAP-positive OCs compared with cells expressing WT PLCγ2 (Figure 7B) or of promoting NFATc1 upregulation (Figure 7C). In contrast, the ability of PLCγ2 H/F to mediate JNK and IκBα phosphorylation was indistinguishable from that of WT PLCγ2 (Figure 7D). These data indicate that PLCγ2 can modulate RANK-mediated signaling independent of its catalytic activity by acting as an adapter molecule. One potential interacting protein is GAB2, which associates with RANK and mediates RANK-induced activation of NF-κB and JNK but not NFATc1 (16). Furthermore, GAB2 has been shown to bind PLCγ2 in mast cells (36). To determine whether PLCγ2 binds to GAB2 in OCs, we reciprocally immunoprecipitated GAB2 and PLCγ2 and found that the 2 molecules associated (Figure 7E). Immunoprecipitation with IgG control antibodies revealed the absence of nonspecific bands (data not shown). To further determine whether PLCγ2 modulates GAB2 activation or its recruitment to RANK, WT and Plcg2^–/– BMMs, treated with RANKL, were immunoprecipitated with an anti-GAB2 Ab (Figure 7F) or with rabbit IgG control Ab (data not shown), followed by immunoblotting with phospho-tyrosine (4G10) and RANK. Results showed that PLCγ2 modulates GAB2 phosphorylation and its association with RANK, suggesting that this may be the mechanism by which PLCγ2 controls AP1 and NF-κB activation.

TNF-α cannot reverse the arrested capacity of PLCγ2-null cells to became OCs. The data presented above show that PLCγ2 is central in RANKL signaling. In OCs, TNF-α appears to be the dominant cytokine mediating inflammatory osteolysis and augments the osteoclastogenic potential of RANKL-exposed OC precursors (3). Due to the capacity of TNF-α to phosphorylate JNK and IκBα in BMMs and OCs (37), we tested its effect in modulating the above-mentioned signaling pathways in cells lacking PLCγ2. TNF-α–mediated phosphorylation of JNK and IκBα occurred similarly in WT and null cells (Figure 8A). Furthermore, TNF-α was not capable of inducing PLCγ2 phosphorylation (Figure 8A), suggesting that the mechanism by which TNF-α regulates JNK and IκBα is PLCγ2 independent. This result prompted us to determine whether TNF-α could rescue the osteoclastogenic defect of Plcg2^–/– cells. Interestingly, while TNF-α augmented RANKL-mediated osteoclastogenesis of WT cells (WT OCs without TNF-α, 19.3 ± 1.5/well; WT OCs with TNF-α, 45.3 ± 1.99/well), the cytokine did not have any effect on the null cells, which remained blocked at the early stage of OC development (Plcg2^–/– OCs, not detected) (Figure 8B). Consistent with this finding, TNF-α, compared with RANKL, was not capable of promoting NFATc1 upregulation in WT or in PLCγ2-null cells (Figure 8C).

Figure 8

TNF-α cannot correct the Plcg2^–/– OC defect. (A) WT and Plcg2^–/– BMMs were stimulated with TNF-α (10 ng/ml) with time. Phosphorylated JNK, IκBα, and PLCγ2 were examined. β-Actin served as control. (B) WT and Plcg2^–/– BMMs were cultured for 3 days with RANKL (100 ng/ml) and M-CSF (10 ng/ml). On day 3 TNF-α was also added to the culture media. Cells were fixed and TRAP stained at day 7. Magnification, ×200. (C) WT and Plcg2^–/– preOCs were stimulated with TNF-α or RANKL for the indicated times, and expression levels of NFATc1, PLCγ2, and β-actin were determined.

The interaction between the immune and skeletal systems is a significant cause of pathological bone loss in rheumatoid arthritis, periodontal diseases, and tumor-associated bone metastasis (38). This exaggerated bone loss is most frequently due to abnormal activation of the immune system, leading to hyperstimulation and differentiation of the OCs (2, 39). The identification of signaling pathways or molecules common to the immune and bone systems could help in designing therapies for the variety of diseases that affect both bone and immunity. Recently, an activating point mutation in the murine PLCγ2 gene has been shown to lead to severe spontaneous inflammation and autoimmunity, mediated by B cells and non-B and non-T hematopoietic cells (40). The chronic inflammation resulted in severe arthritis of the small joints, leading to phalangeal erosion (40). This observation suggested that the activating mutation in PLCγ2 gene could also be responsible for the hyperactivation and recruitment of the OCs at the inflammatory sites.

In this study we have identified what we believe to be a novel role for the immunomodulatory protein PLCγ2 as a key factor in the regulation of bone homeostasis. Targeted deletion of Plcg2 led to increased bone mass due to blockade of OC differentiation in unmanipulated mice, with decreased RANKL-mediated signaling to AP1 and NF-κB and defective upregulation of NFATc1, independent of PLCγ1. Despite the presence of normal levels of PLCγ1 in the PLCγ2-null cells, PLCγ1 could not compensate for the lack of its cognate isoform. Furthermore, we found that PLCγ2, and not PLCγ1, was phosphorylated by RANKL. This result suggests that the 2 PLCγ isoforms exert different, nonoverlapping functions in OCs.

Differential regulation of the 2 PLCγ isoforms within the same cell type has been previously demonstrated in platelets, where activation of glycoprotein VI by collagen resulted in a substantial increase in tyrosine phosphorylation of PLCγ2 but not PLCγ1 (41, 42). Since activation of PLCγ isoforms is tightly regulated by the action of a number of receptor tyrosine kinases (RTKs) (24–26), we asked whether M-CSF, via its receptor c-Fms, could lead to phosphorylation of PLCγ1, PLCγ2, or both. We found that PLCγ1, and to a lesser extent PLCγ2, was phosphorylated by M-CSF. In support of this finding, analysis of Plcg1^–/– ES cells generated few hematopoietic cells with a reduced level of monocyte/macrophage differentiation (29). Furthermore, we did not detect an M-CSF–dependent proliferative defect in BMMs and OCs lacking PLCγ2, and we observed that M-CSF–mediated activation of ERK and JNK occurred normally. These results indicate that PLCγ2 is not involved in M-CSF signaling and suggest that PLCγ1 may regulate this pathway in OC lineage cells.

The phosphorylation of PLCγ2 in response to RANKL was mediated in an SFK-dependent manner. PP2, a well-known Src kinase inhibitor, completely blocked RANKL-mediated PLCγ2 activation. Moreover Dap12 was required for phosphorylation of PLCγ2 in response to RANKL stimulation. It is possible that SFKs phosphorylate PLCγ2 directly. However, it is more likely that SFKs phosphorylate the tyrosine residues in the ITAM motif of Dap12, leading to recruitment and activation of Syk, which in turn can activate PLCγ, as occurs in other cell types (B cells and mast cells) (43, 44). We did not determine which Src family member is involved in PLCγ2 activation, since the inhibitor used blocked various SFKs. These results indicate that PLCγ isoforms are differentially phosphorylated in OCs, PLCγ2 primarily by RANKL and PLCγ1 by M-CSF.

AP1, NF-κB, and NFATc1 are members of well-described osteoclastogenic pathways activated by RANKL. We found that PLCγ2 differentially regulates the activation of all them. On one hand, inhibition of PLCγ2 catalytic activity by U73122 completely abrogated NFATc1 expression in osteoclastic cells but had no effect on activation of JNK or phosphorylation of IκBα. On the other hand, we found that p65 translocation into the nucleus and consequent NF-κB activation determined by EMSA were virtually absent in PLCγ2-deficient BMMs. Similarly, phospho-JNK levels, nuclear translocation of phospho–c-Jun, and thus activation of AP1 were also aberrant in the null cells. Therefore, these data suggest PLCγ2 catalytic activity is required for NFATc1 expression but not for JNK and IκBα phosphorylation. In agreement with this hypothesis, a catalytically inactive mutant of PLCγ2 could rescue neither the osteoclastogenic defect of cells lacking PLCγ2 nor NFATc1 upregulation, while being sufficient to promote JNK and IκBα phosphorylation in response to RANKL. Interestingly, the finding that PLCγ2 is activated by RANKL downstream of Dap12 and governs all the above-mentioned signaling pathways differs from the data obtained with cells lacking Dap12 and FcRγ. In fact, Dap12^–/–FcRγ^–/– OCs displayed normal RANKL-mediated phosphorylation of JNK, c-Jun, and IκBα, while NFATc1 upregulation was absent (20). These results suggest that PLCγ2 may not be uniquely involved in the signaling cascade downstream of Dap12/FcRγ receptor and in fact indicate that PLCγ2 regulates JNK and IκBα phosphorylation downstream of RANKL independent of Dap12/FcRγ.

The adapter protein GAB2 has been shown to be a crucial component of RANK signaling and osteoclastogenesis and is required for activation of NF-κB and JNK, but not NFATc1, pathways (16). Based on the observation that PLCγ2 forms a complex with GAB2 in OCs and in other cell types (36), we hypothesized that PLCγ2 could regulate some RANKL signaling pathways by acting as an adapter molecule. One possibility is that PLCγ2 modulates the GAB2/RANK complex. In support of this hypothesis, we found that PLCγ2 is required for GAB2 phosphorylation and mediates GAB2 recruitment to RANK, suggesting that AP1 and NF-κB activation might be dependent on the capacity of PLCγ2 to form a complex with GAB2. In addition, the finding that the PLC inhibitor U73122, which blocks IP3-mediated calcium influx (45), and a catalytically inactive form of PLCγ2 completely abrogate osteoclastogenesis by affecting NFATc1 upregulation suggest that both the catalytic activity and the adapter function of PLCγ2 are required for osteoclastogenesis. Thus, overall our data support the model (Figure 9) in which the catalytic activity of PLCγ2 is required for NFATc1 upregulation downstream of the ITAM motif of Dap12, while PLCγ2, acting as an adapter molecule, mediates GAB2 phosphorylation and its recruitment to RANK, leading to AP1 and NF-κB activation.

Figure 9

PLCγ2 in RANKL signaling. PLCγ2 is phosphorylated by RANKL in an SFK-dependent manner downstream of Dap12/FcRγ. Activation of PLCγ2 and PLCγ2 catalytic activity are required for NFATc1 upregulation (right arm). PLCγ2 can also bind GAB2 and modulate its activation and recruitment to the RANK-signaling complex (left arm). This interaction might be required for activation of the IκBα/NF-κB and JNK/AP1 pathways independent of Dap12/FcRγ.

The specific requirement of PLCγ2 for activation of NF-κB, AP1, and NFATc1 signaling pathways is manifested in a basal in vivo osteopetrotic phenotype characterized by defective OC recruitment. Although the number of OCs in vivo was significantly reduced in Plcg2-null compared with WT animals, the presence of a few TRAP-positive cells could reflect the presence of a milieu of cytokines circulating in vivo that partially rescue the differentiation of PLCγ2-null OCs. TNF-α potently stimulates osteoclastogenesis by augmenting RANKL-mediated signaling pathways (46). TNF-α can also induce JNK and IκBα phosphorylation (37). Thus, we sought to determine whether TNF-α could reverse the ability of the PLCγ2-null cells to become OCs. Interestingly, while TNF-α could activate JNK and IκBα in Plcg2^–/– BMMs, it could not reverse their differentiation defect, most likely due to the inability of TNF-α to induce NFATc1 upregulation. In conclusion, our data indicate that PLCγ2 is required for the maintenance of bone homeostasis and RANKL-mediated osteoclastogenesis both in vitro and in vivo.

Previous studies reported that Plcg2^–/– mice have defective B cell maturation and mast cell activation (29). The inability of Plcg2^–/– cells to respond to both basal and inflammation-mediated osteoclastogenesis in vitro clearly supports the important role of PLCγ2 in osteoclast differentiation. Thus, the intrinsic defect of Plcg2^–/– OCs together with the deficient B cell–mediated immune response suggest that targeting PLCγ2 could be a novel approach for antiresorptive therapies. Antirheumatic therapies directed to selectively deplete human CD20-positive B cells (e.g., Rituximab) or to directly target OC activation and function (RANKL inhibitors and bisphosphonates) have been very useful approaches in recent clinical trials (47). However, in most cases, only a combination of both treatments will resolve both the inflammatory and the ongoing osteolytic responses. Thus, PLCγ2 becomes an interesting target for the cure of rheumatoid diseases due to its dual role in the activation of a particular subset of immune cells, B lymphocytes, and for its capacity to control OC development in vivo. Therefore, a combined therapy affecting both the inflammatory and the osteolytic components of the rheumatoid disease might increase the hope that disease modification and remission in rheumatoid arthritis is a realistic goal.

We gratefully acknowledge Yousef Abu-Amer (Department of Orthopaedic Surgery, Washington University) and Marco Colonna (Department of Pathology and Immunology, Washington University) for helpful suggestions and discussion; James N. Ihle for Plcg2^–/– mice (St. Jude Children’s Research Hospital, Memphis, Tennessee, USA); and Matilda Katan for the full-length PLCγ2 construct (Cancer Research UK Centre for Cell and Molecular Biology, Chester Beatty Laboratories). This work was supported by departmental funding from the Orthopaedic Surgery Department, Washington University School of Medicine; by the Arthritis Foundation (R. Faccio); by an American Society for Bone and Mineral Research career award (to R. Faccio); and by NIH grants (AR47846 and AR48335 to D.V. Novack and AR52921 to R. Faccio).

Address correspondence to: Roberta Faccio, Washington University School of Medicine, Department of Orthopaedic Surgery, Campus Box 8233, 1 Barnes Jewish Hospital Plaza, Suite 11300, St. Louis, Missouri 63110, USA. Phone: (314) 747-4602; Fax: (314) 362-0334; E-mail: faccior@wustl.edu.

Nonstandard abbreviations used: AP1, activator protein–1; BMM, BM macrophage; FcRγ, Fc receptor γ; IP3, inositol-1,4,5-triphosphate; ITAM, immune receptor tyrosine activation motif; NFATc1, nuclear factor of activated T cells c1; OB, osteoblast; OC, osteoclast; PLC, phospholipase C; RANK, receptor activator of NF-κB; RANKL, RANK ligand; SFK, Src family kinase; TRAP, tartrate-resistant acid phosphatase.

Conflict of interest: The authors have declared that no conflict of interest exists.

Reference information: J. Clin. Invest.116:2869–2879 (2006). doi:10.1172/JCI28775

1. Goldring, S.R., Gravallese, E.M. 2000. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res. 2:33-37.
   View this article via: PubMed CrossRef Google Scholar
2. Teitelbaum, S.L., Ross, F.P. 2003. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4:638-649.
   View this article via: PubMed CrossRef Google Scholar
3. Zhang, Y.-H., Heulsmann, A., Tondravi, M.M., Mukherjee, A., Abu-Amer, Y. 2001. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 276:563-568.
   View this article via: PubMed CrossRef Google Scholar
4. Kitaura, H., et al. 2005. M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest. 115:3418-3427.
   View this article via: JCI CrossRef PubMed Google Scholar
5. O’ Gradaigh, D., Ireland, D., Bord, S., Compston, J.E. 2004. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann. Rheum. Dis. 63:354-359.
   View this article via: PubMed CrossRef Google Scholar
6. Wei, S., Kitaura, H., Zhou, P., Ross, F.P., Teitelbaum, S.L. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115:282-290.
   View this article via: JCI CrossRef PubMed Google Scholar
7. Tanaka, S., Nakamura, K., Takahasi, N., Suda, T. 2005. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev. 208:30-49.
   View this article via: PubMed CrossRef Google Scholar
8. Karin, M., Cao, Y., Greten, F.R., Li, Z.-W. 2002. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer. 2:301-310.
   View this article via: PubMed CrossRef Google Scholar
9. David, J.P., Sabapathy, K., Hoffmann, O., Idarraga, M.H., Wagner, E.F. 2002. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci. 115:4317-4325.
   View this article via: PubMed CrossRef Google Scholar
10. Ruocco, M.G., et al. 2005. IkappaB kinase (IKK)beta, but not IKKalpha, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201:1677-1687.
    View this article via: PubMed CrossRef Google Scholar
11. Dai, S., Hirayama, T., Abbas, S., Abu-Amer, Y. 2004. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 279:37219-37222.
    View this article via: PubMed CrossRef Google Scholar
12. Jimi, E., et al. 2004. Selective inhibition of NF-kappaB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10:617-624.
    View this article via: PubMed CrossRef Google Scholar
13. Iotsova, V., et al. 1997. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3:1285-1289.
    View this article via: PubMed CrossRef Google Scholar
14. Franzoso, G., et al. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11:3482-3496.
    View this article via: PubMed CrossRef Google Scholar
15. Grigoriadis, A.E., et al. 1994. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 266:443-448.
    View this article via: PubMed CrossRef Google Scholar
16. Wada, T., et al. 2005. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat. Med. 11:394-399.
    View this article via: PubMed CrossRef Google Scholar
17. Asagiri, M., et al. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202:1261-1269.
    View this article via: PubMed CrossRef Google Scholar
18. Takayanagi, H., et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell. 3:889-901.
    View this article via: PubMed CrossRef Google Scholar
19. Ikeda, F., et al. 2004. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114:475-484.
    View this article via: JCI CrossRef PubMed Google Scholar
20. Koga, T., et al. 2004. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 428:758-763.
    View this article via: PubMed CrossRef Google Scholar
21. Kaifu, T., et al. 2003. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J. Clin. Invest. 111:323-332.
    View this article via: JCI CrossRef PubMed Google Scholar
22. Mocsai, A., et al. 2004. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci. U. S. A. 101:6158-6163.
    View this article via: PubMed CrossRef Google Scholar
23. Humphrey, M.B., et al. 2004. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J. Bone Miner. Res. 19:224-234.
    View this article via: PubMed CrossRef Google Scholar
24. Wilde, J.I., Watson, S.P. 2001. Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other? Cell. Signal. 13:691-701.
    View this article via: PubMed CrossRef Google Scholar
25. Rebecchi, M.J., Pentyala, S.N. 2000. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol. Rev. 80:1291-1335.
    View this article via: PubMed Google Scholar
26. Katan, M. 1998. Families of phosphoinositide-specific phospholipase C: structure and function. Biochim. Biophys. Acta. 1436:5-17.
    View this article via: PubMed Google Scholar
27. Katan, M. 2005. New insights into the families of PLC enzymes: looking back and going forward. Biochem. J. 391:e7-e9.
    View this article via: PubMed CrossRef Google Scholar
28. Ji, Q.S., et al. 1997. Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development. Proc. Natl. Acad. Sci. U. S. A. 94:2999-3003.
    View this article via: PubMed CrossRef Google Scholar
29. Wang, D., et al. 2000. Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity. 13:25-35.
    View this article via: PubMed CrossRef Google Scholar
30. Hashimoto, A., et al. 2000. Cutting edge: essential role of phospholipase C-gamma 2 in B cell development and function. J. Immunol. 165:1738-1742.
    View this article via: PubMed Google Scholar
31. Tassi, I., et al. 2005. Phospholipase C-gamma 2 is a critical signaling mediator for murine NK cell activating receptors. J. Immunol. 175:749-754.
    View this article via: PubMed Google Scholar
32. Takayanagi, H., et al. 2000. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43:259-269.
    View this article via: PubMed CrossRef Google Scholar
33. Antony, P., et al. 2004. B-cell antigen receptor activates transcription factors NFAT (nuclear factor of activated T-cells) and NF-kappaB (nuclear factor kappaB) via a mechanism that involves diacylglycerol. Biochem. Soc. Trans. 32:113-115.
    View this article via: PubMed CrossRef Google Scholar
34. Faccio, R., Zou, W., Colaianni, G., Teitelbaum, S.L., Ross, F.P. 2003. High dose M-CSF partially rescues the Dap12–/– osteoclast phenotype. J. Cell. Biochem. 90:871-883.
    View this article via: PubMed CrossRef Google Scholar
35. Smith, M.R., et al. 1994. Phospholipase C-gamma 1 can induce DNA synthesis by a mechanism independent of its lipase activity. Proc. Natl. Acad. Sci. U. S. A. 91:6554-6558.
    View this article via: PubMed CrossRef Google Scholar
36. Xie, Z.H., Ambudkar, I., Siraganian, R.P. 2002. The adapter molecule Gab2 regulates Fc epsilon RI-mediated signal transduction in mast cells. J. Immunol. 168:4682-4691.
    View this article via: PubMed Google Scholar
37. Wei, S., Wang, M.W., Teitelbaum, S.L., Ross, F.P. 2002. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and MAP kinase signaling. J. Biol. Chem. 21:6622-6630.
38. Arron, J.R., Choi, Y. 2000. Bone versus immune system. Nature. 408:535-536.
    View this article via: PubMed CrossRef Google Scholar
39. Wiebe, S.H., Hafezi, M., Sandhu, H.S., Sims, S.M., Dixon, S.J. 1996. Osteoclast activation in inflammatory periodontal diseases. Oral Dis. 2:167-180.
    View this article via: PubMed Google Scholar
40. Yu, P., et al. 2005. Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry. Immunity. 22:451-465.
    View this article via: PubMed CrossRef Google Scholar
41. Blake, R.A., Asselin, J., Walker, T., Watson, S.P. 1994. Fc gamma receptor II stimulated formation of inositol phosphates in human platelets is blocked by tyrosine kinase inhibitors and associated with tyrosine phosphorylation of the receptor. FEBS Lett. 342:15-18.
    View this article via: PubMed CrossRef Google Scholar
42. Daniel, J.L., Dangelmaier, C., Smith, J.B. 1994. Evidence for a role for tyrosine phosphorylation of phospholipase C gamma 2 in collagen-induced platelet cytosolic calcium mobilization. Biochem. J. 302:617-622.
    View this article via: PubMed Google Scholar
43. Tamir, I., Cambier, J.C. 1998. Antigen receptor signaling: integration of protein tyrosine kinase functions. Oncogene. 17:1353-1364.
    View this article via: PubMed CrossRef Google Scholar
44. Sada, K., Yamamura, H. 2003. Protein-tyrosine kinases and adaptor proteins in FcepsilonRI-mediated signaling in mast cells. Curr. Mol. Med. 3:85-94.
    View this article via: PubMed CrossRef Google Scholar
45. Bleasdale, J.E., et al. 1989. Inhibition of phospholipase C dependent processes by U-73, 122. Adv. Prostaglandin Thromboxane Leukot. Res. 19:590-593.
    View this article via: PubMed Google Scholar
46. Lam, J., et al. 2000. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481-1488.
    View this article via: JCI PubMed CrossRef Google Scholar
47. Genovese, M.C. 2005. Biologic therapies in clinical development for the treatment of rheumatoid arthritis. J. Clin. Rheumatol. 11:S45-S54.
    View this article via: PubMed CrossRef Google Scholar
48. Faccio, R., Novack, D.V., Zallone, A., Ross, F.P., Teitelbaum, S.L. 2003. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by b3 integrin. J. Cell Biol. 162:499-509.
    View this article via: PubMed CrossRef Google Scholar
49. Faccio, R., Zallone, A., Ross, F.P., Teitelbaum, S.L. 2003. c-Fms and the avb3 integrin collaborate during osteoclast differentiation. J. Clin. Invest. 111:749-758.
    View this article via: JCI CrossRef PubMed Google Scholar